Hossein Taghizadeh
Overview
Explore the profile of Hossein Taghizadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taghizadeh H, Fajkovic H
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075730
Penile cancer, though a rare malignancy, presents a significant challenge in the domain of male genitourinary oncology, particularly due to its limited treatment options and due to the profound physical...
2.
Reimann P, Mavroeidi I, Burghofer J, Taghizadeh H, Webersinke G, Kasper S, et al.
Cancer Immunol Immunother
. 2024 Oct;
73(12):251.
PMID: 39358611
Introduction: This study assesses the effectiveness of durvalumab with platinum and gemcitabine for biliary tract cancers (BTC). It aims to confirm the TOPAZ-1 trial results in a real-world context and...
3.
Hochmair M, Terbuch A, Lang D, Trockenbacher C, Augustin F, Ghanim B, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061224
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018-December 2021 at 16 leading hospital...
4.
Taghizadeh H, Dong Y, Gruenberger T, Prager G
Ther Adv Med Oncol
. 2024 Apr;
16:17588359241230756.
PMID: 38559612
Due to the fact biliary tract cancer (BTC) is often diagnosed at an advanced stage, thus, not eligible for resection, and due to the aggressive tumor biology, it is considered...
5.
Doleschal B, Taghizadeh H, Webersinke G, Piringer G, Schreil G, Decker J, et al.
Sci Rep
. 2023 Sep;
13(1):15421.
PMID: 37723192
Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic options, especially after the failure of first-line systemic treatment. Targeted treatments for this clinical situation...
6.
Taghizadeh H, Djanani A, Eisterer W, Gerger A, Gruenberger B, Gruenberger T, et al.
Front Oncol
. 2023 Sep;
13:1225154.
PMID: 37711201
Locally advanced or metastatic cholangiocarcinoma is an aggressive carcinoma with a dismal prognosis. For the first-line treatment of locally advanced or metastatic cholangiocarcinoma, cisplatin/gemcitabine has been the standard of care...
7.
Taghizadeh H, Schmalfuss T, Maj-Hes A, Singer J, Prager G
Front Oncol
. 2023 May;
13:1143825.
PMID: 37234989
Introduction: Metastatic biliary tract cancer (BTC) is a rare and aggressive entity associated with poor prognosis. It represents a major challenge for adequate treatment strategies. In recent years, BTC has...
8.
Taghizadeh H, Maj-Hes A, Prager G, Mullauer L, Mader R
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454843
In this analysis, we examined the efficacy, feasibility, and limitations of the application of mTOR inhibitors based on the individual molecular profiles of pretreated cancer patients after the failure of...
9.
Taghizadeh H, Prager G
Curr Cancer Drug Targets
. 2022 Feb;
22(8):639-650.
PMID: 35168521
BTC is a rare and aggressive cancer disease, bearing an overall dismal prognosis with only finite therapy options. Only combination chemotherapy regimens achieve disease control, which is often only short-lived...
10.
Taghizadeh H, Mader R, Mullauer L, Erhart F, Kautzky-Willer A, Prager G
J Pers Med
. 2020 Dec;
10(4).
PMID: 33322358
In this analysis, we examined the efficacy, feasibility, and limitations of molecular-based targeted therapies in heavily pretreated metastatic colorectal cancer (mCRC) patients after failure of all standard treatments. In this...